HK1206646A1 - Dosage forms of halofuginone and methods of use - Google Patents

Dosage forms of halofuginone and methods of use Download PDF

Info

Publication number
HK1206646A1
HK1206646A1 HK15107438.8A HK15107438A HK1206646A1 HK 1206646 A1 HK1206646 A1 HK 1206646A1 HK 15107438 A HK15107438 A HK 15107438A HK 1206646 A1 HK1206646 A1 HK 1206646A1
Authority
HK
Hong Kong
Prior art keywords
dosage forms
halofuginone
methods
subjects
oral
Prior art date
Application number
HK15107438.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ernest D. BUSH
Diane Mcguire
Marc B. BLAUSTEIN
Original Assignee
Halo Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halo Therapeutics, Llc filed Critical Halo Therapeutics, Llc
Publication of HK1206646A1 publication Critical patent/HK1206646A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15107438.8A 2012-03-29 2013-03-29 Dosage forms of halofuginone and methods of use HK1206646A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261617356P 2012-03-29 2012-03-29
US61/617,356 2012-03-29
US201361798784P 2013-03-15 2013-03-15
US61/798,784 2013-03-15
PCT/US2013/034616 WO2013149148A2 (en) 2012-03-29 2013-03-29 Dosage forms of halofuginone and methods of use

Publications (1)

Publication Number Publication Date
HK1206646A1 true HK1206646A1 (en) 2016-01-15

Family

ID=49261398

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107438.8A HK1206646A1 (en) 2012-03-29 2013-03-29 Dosage forms of halofuginone and methods of use

Country Status (9)

Country Link
US (2) US20150086627A1 (enExample)
EP (1) EP2830628A4 (enExample)
JP (2) JP2015517994A (enExample)
CN (1) CN104640546A (enExample)
AU (2) AU2013237881B2 (enExample)
CA (1) CA2869054A1 (enExample)
HK (1) HK1206646A1 (enExample)
IL (1) IL234841A0 (enExample)
WO (1) WO2013149148A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335573B2 (en) 2015-12-02 2019-07-02 Cook Medical Technologies Llc Intraperitoneal chemotherapy medical devices, kits, and methods
CN106539754A (zh) * 2016-11-25 2017-03-29 河北科星药业有限公司 氢溴酸常山酮溶液及其制备方法
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
CN109793741B (zh) * 2019-03-11 2021-02-26 中国农业科学院兰州兽医研究所 一种常山酮在制备预防口蹄疫病毒感染的药物中的应用
WO2022040566A1 (en) * 2020-08-21 2022-02-24 The Regents Of The University Of California Methods and uses of halofuginone
CN113880860B (zh) * 2021-12-08 2022-02-22 北京肿瘤医院(北京大学肿瘤医院) 常山酮衍生物及其药物组合物和用途
CN114469956B (zh) * 2022-01-29 2023-07-18 中国科学技术大学 常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用
CN116392493A (zh) * 2023-02-02 2023-07-07 四川大学华西医院 一种关于天然活性化合物hf诱导atc细胞凋亡的应用
CN119215052B (zh) * 2024-09-03 2025-09-02 南方医科大学南方医院 常山酮在制备治疗异位骨化的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512410B2 (enExample) * 1974-02-27 1980-04-02
JPS5732230A (en) * 1980-07-18 1982-02-20 Parke Davis & Co Instetine-soluble capsule
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
ATE425744T1 (de) * 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
WO2004039308A2 (en) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Quinazolinone compositions for regulation of gene expression related to pathological processes
CN100591336C (zh) * 2002-11-08 2010-02-24 汪建平 菱角提取物及其使用方法
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
US20050208134A1 (en) * 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
EP2114409B1 (en) * 2007-01-21 2013-11-20 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
TWI478710B (zh) * 2007-11-30 2015-04-01 Univ California 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法
CN102177152A (zh) * 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途

Also Published As

Publication number Publication date
AU2018200167A1 (en) 2018-02-01
WO2013149148A2 (en) 2013-10-03
JP2018203790A (ja) 2018-12-27
EP2830628A2 (en) 2015-02-04
JP2015517994A (ja) 2015-06-25
WO2013149148A8 (en) 2013-11-14
AU2013237881B2 (en) 2017-10-12
EP2830628A4 (en) 2016-05-25
IL234841A0 (en) 2014-12-31
WO2013149148A3 (en) 2015-04-16
US20150086627A1 (en) 2015-03-26
CA2869054A1 (en) 2013-10-03
AU2013237881A1 (en) 2014-10-16
CN104640546A (zh) 2015-05-20
US20180193276A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
WO2013149148A8 (en) Dosage forms of halofuginone and methods of use
EP2702994A3 (en) Methods of administering pirfenidone therapy
HK1215681A1 (zh) 使用白细胞介素-10治疗疾病和病症的方法
EP3164114A4 (en) Purified therapeutic nanoparticles and preparation methods thereof
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
IN2014DN09434A (enExample)
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
ZA201501977B (en) Orally administered medical composition
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
EP2605698A4 (en) Central site photoplethysmography, medication administration, and safety
WO2012154885A3 (en) Carbonic anhydrase targeting agents and methods of using same
IL273365B (en) Subcutaneous administration of adamts13
EP2997165A4 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
EP3229824A4 (en) Oral octreotide administered in combination with other therapeutic agents
EP3285771A4 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
WO2014179771A8 (en) Dosing combinations for reducing undesired humoral immune responses
HK1223630A1 (zh) 抗-egfr疗法的实施与用量
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer
WO2012145234A3 (en) Cyclopropyl derivatives and methods of use
WO2012173781A3 (en) Methods of treating glucose metabolism disorders